Tìm theo
SCH-530348
platelet aggregation inhibitors
Thuốc Gốc
Small Molecule
SCH 530348 is new oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of atherothrombotic events in patients with Acute Coronary Syndrome (ACS), previous Myocardial Infarction (MI), stroke, or existing peripheral arterial disease. On the back of successful phase II clinical trials, SCH 530348 has now progressed to phase III development, where it is being evaluated in two large-scale trials involving almost 30,000 cardiac patients.
Cơ Chế Tác Dụng : SCH 530348 is new oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of atherothrombotic events in patients with Acute Coronary Syndrome (ACS), previous Myocardial Infarction (MI), stroke, or existing peripheral arterial disease. On the back of successful phase II clinical trials, SCH 530348 has now progressed to phase III development, where it is being evaluated in two large-scale trials involving almost 30,000 cardiac patients. SCH-530348 is a thrombin receptor antagonist (TRA). It blocks the platelet PAR-1 receptor to which thrombin binds, thus inhibiting thrombin-induced activation of platelets.
Chỉ Định : Investigated for use/treatment in cardiovascular disorders.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05692
... loading
... loading